InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study
January 19 2017 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced that a new patient has been enrolled into The
INSPIRE Study (InVivo Study of Probable Benefit of
the Neuro-Spinal Scaffold™ for Safety and Neurologic
Recovery in Subjects with Complete Thoracic AIS A Spinal
Cord Injury). Travis Dumont, M.D., an INSPIRE Principal
Investigator, performed the implantation on January 16, 2017,
approximately 67 hours after the injury occurred.
“The implantation procedure of the Neuro-Spinal Scaffold was
successful, and the patient is doing well,” Dr. Dumont said. “I
look forward to following the patient’s progress going
forward.”
Mark Perrin, InVivo’s Chief Executive Officer and Chairman,
said, “We are pleased at the rate of enrollment into INSPIRE over
the past few months. We now have eleven patients enrolled and in
follow up, and with a steady flow of new sites we expect enrollment
to increase in the coming months.”
For more information, please visit the company’s
ClinicalTrials.gov registration
site:http://clinicaltrials.gov/ct2/show/study/NCT02138110
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the
biodegradable Neuro-Spinal Scaffold within the decompressed and
debrided injury epicenter is intended to support appositional
healing, thereby reducing post-traumatic cavity formation, sparing
white matter, and allowing neural regeneration across the healed
wound epicenter. The Neuro-Spinal Scaffold, an investigational
device, has received a Humanitarian Use Device (HUD) designation
and currently is being evaluated in the INSPIRE pivotal probable
benefit study for the treatment of patients with complete (AIS A)
traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. In
2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. These statements
can be identified by words such as "believe," "anticipate,"
"intend," "estimate," "will," "may," "should," "expect," “designed
to,” “potentially,” and similar expressions, and include statements
regarding the expected pace of enrollment in the INSPIRE study. Any
forward-looking statements contained herein are based on current
expectations, and are subject to a number of risks and
uncertainties. Factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the company’s
ability to successfully open additional clinical sites for
enrollment and to enroll additional patients; the timing of the
Institutional Review Board process; the company’s ability to
commercialize its products; the company’s ability to develop,
market and sell products based on its technology; the expected
benefits and efficacy of the company’s products and technology in
connection with the treatment of spinal cord injuries; the
availability of substantial additional funding for the company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and other
risks associated with the company’s business, research, product
development, regulatory approval, marketing and distribution plans
and strategies identified and described in more detail in the
company’s Annual Report on Form 10-K for the year ended December
31, 2015, and its other filings with the SEC, including the
company’s Form 10-Qs and current reports on Form 8-K. The company
does not undertake to update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170119005366/en/
InVivo TherapeuticsBrian Luque, 617-863-5535Investor
Relationsbluque@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024